Theravance Biopharma (TBPH) Gains from Sales and Divestitures (2018 - 2026)
Theravance Biopharma (TBPH) reported Gains from Sales and Divestitures of $720320.0 for Q1 2026, up 16.36% year-over-year from $619026.0 in Q1 2025, and down 60.73% quarter-over-quarter from $1.8 million in Q4 2025.
Theravance Biopharma (TBPH) Gains from Sales and Divestitures (2018 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 8 years of Gains from Sales and Divestitures data on file, last reported at $720320.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $720320.0, up 16.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $720320.0 (up 16.36% YoY), and the FY2025 annual result was $1.8 million, up 11.8% from the prior year.
- Gains from Sales and Divestitures retreated to $720320.0 in Q1 2026 per TBPH's latest filing, from $1.8 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $3.8 million in Q4 2022 and troughed at $297284.0 in Q3 2024.
- A 5-year average of $1.1 million and a median of $656431.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures soared 809.87% in 2022, then plunged 56.17% in 2023.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $3.8 million in 2022, then sank by 56.17% to $1.7 million in 2023, then dropped by 0.64% to $1.6 million in 2024, then rose by 11.8% to $1.8 million in 2025, then plunged by 60.73% to $720320.0 in 2026.
- Business Quant data shows TBPH's Gains from Sales and Divestitures at $720320.0 in Q1 2026, $1.8 million in Q4 2025, and $336744.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Theravance Biopharma | 839.69 Mn | 445.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 720,320.00 |
| Mar 31, 2026 | 720,320.00 |
| Dec 31, 2025 | 1.83 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 336,744.00 |
| Sep 30, 2025 | 336,744.00 |
| Jun 30, 2025 | 413,240.00 |
| Jun 30, 2025 | 413,240.00 |
| Mar 31, 2025 | 619,026.00 |
| Mar 31, 2025 | 619,026.00 |
| Dec 31, 2024 | 1.64 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 297,284.00 |
| Sep 30, 2024 | 297,284.00 |
| Jun 30, 2024 | 357,038.00 |
| Jun 30, 2024 | 357,038.00 |
| Mar 31, 2024 | 656,431.00 |
| Mar 31, 2024 | 656,431.00 |
| Dec 31, 2023 | 1.65 Mn |
| Dec 31, 2023 | 1.65 Mn |